Scholar Rock Q3 net loss $102.2M; Type A FDA meeting positive for apitegromab BLA resubmission in 2026

Scholar Rock Holding Corp

2025-Q3 EPS reported -$2.54

Net loss $102.2M (EPS -$0.90) vs $64.5M (EPS -$0.66) YoY; no revenue.
Cash $369.6M; plus ~$60M from warrants expiring Dec 31, 2025, expected to fund into 2027.
Type A meeting with FDA completed Nov 12; BLA resubmission and U.S. launch for apitegromab in SMA anticipated in 2026.
Second U.S. fill-finish facility secured; commercial capacity reserved starting Q1 2026.
FDA cleared IND for SRK-439; dosing in healthy volunteers to begin Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.